CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹25 Cr | ₹-107 Cr | ₹99 Cr | ₹-45 Cr |
What is the latest Cash Flow from Financing Activities ratio of CORONA REMEDIES ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹25 Cr |
| Mar2025 | ₹-107 Cr |
| Mar2024 | ₹99 Cr |
| Mar2023 | ₹-45 Cr |
How is Cash Flow from Financing Activities of CORONA REMEDIES Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹25 Cr | Positive | |
| Mar2025 | ₹-107 Cr | Negative | |
| Mar2024 | ₹99 Cr | Positive | |
| Mar2023 | ₹-45 Cr | - | |
Compare Cash Flow from Financing Activities of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹13,398.5 Cr | 3.1% | 4% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹448,316.0 Cr | -1.9% | -3.7% | 18.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹251,737.0 Cr | 2.6% | 11.1% | 56% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹187,594.0 Cr | 0.2% | 1.3% | 38% | Stock Analytics | |
| CIPLA | ₹110,515.0 Cr | -1.5% | -6.4% | -12.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,420.6 Cr | -1% | -5.1% | -8.1% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 3.1% |
4% |
|
| SENSEX | -2.4% |
-4.8% |
-7.2% |
You may also like the below Video Courses